258 related articles for article (PubMed ID: 33171078)
1. Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line.
Kim J; Luo H; White W; Rees W; Venkat R; Albarghouthi M
MAbs; 2020; 12(1):1844928. PubMed ID: 33171078
[TBL] [Abstract][Full Text] [Related]
2. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
3. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
4. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
5. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.
Goetze AM; Liu YD; Zhang Z; Shah B; Lee E; Bondarenko PV; Flynn GC
Glycobiology; 2011 Jul; 21(7):949-59. PubMed ID: 21421994
[TBL] [Abstract][Full Text] [Related]
6. The effect of Fc glycan forms on human IgG2 antibody clearance in humans.
Chen X; Liu YD; Flynn GC
Glycobiology; 2009 Mar; 19(3):240-9. PubMed ID: 18974198
[TBL] [Abstract][Full Text] [Related]
7. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
Branstetter E; Duff RJ; Kuhns S; Padaki R
FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
[TBL] [Abstract][Full Text] [Related]
8. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods.
Reusch D; Haberger M; Falck D; Peter B; Maier B; Gassner J; Hook M; Wagner K; Bonnington L; Bulau P; Wuhrer M
MAbs; 2015; 7(4):732-42. PubMed ID: 25996192
[TBL] [Abstract][Full Text] [Related]
9. At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody.
Yu C; Gao K; Zhu L; Wang W; Wang L; Zhang F; Liu C; Li M; Wormald MR; Rudd PM; Wang J
Sci Rep; 2016 Jan; 7():20029. PubMed ID: 26823113
[TBL] [Abstract][Full Text] [Related]
10. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
11. Highly sensitive HPLC analysis and biophysical characterization of N-glycans of IgG-Fc domain in comparison between CHO and 293 cells using FcγRIIIa ligand.
Kosuge H; Nagatoishi S; Kiyoshi M; Ishii-Watabe A; Tanaka T; Terao Y; Oe S; Ide T; Tsumoto K
Biotechnol Prog; 2020 Nov; 36(6):e3016. PubMed ID: 32390308
[TBL] [Abstract][Full Text] [Related]
12. Assessing Fc glycan heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC.
Raju TS
Methods Mol Biol; 2013; 988():169-80. PubMed ID: 23475719
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods.
Reusch D; Haberger M; Maier B; Maier M; Kloseck R; Zimmermann B; Hook M; Szabo Z; Tep S; Wegstein J; Alt N; Bulau P; Wuhrer M
MAbs; 2015; 7(1):167-79. PubMed ID: 25524468
[TBL] [Abstract][Full Text] [Related]
14. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
15. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization.
Huang L; Biolsi S; Bales KR; Kuchibhotla U
Anal Biochem; 2006 Feb; 349(2):197-207. PubMed ID: 16360109
[TBL] [Abstract][Full Text] [Related]
16. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
17. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.
Lee HS; Im W
Sci Rep; 2017 Oct; 7(1):12659. PubMed ID: 28978918
[TBL] [Abstract][Full Text] [Related]
18. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
19. N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance.
Higel F; Sandl T; Kao CY; Pechinger N; Sörgel F; Friess W; Wolschin F; Seidl A
Eur J Pharm Biopharm; 2019 Jun; 139():123-131. PubMed ID: 30905778
[TBL] [Abstract][Full Text] [Related]
20. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
